Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib

A 59-year-old man who was receiving lenvatinib as a third-line tyrosine kinase inhibitor to treat hepatocellular carcinoma and multiple bone metastases complained of general fatigue four months after starting lenvatinib. A blood examination showed unexpectedly elevated serum C-reactive protein (CRP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Honda, Shuya, Saito, Yoshinori, Sawada, Koji, Hasebe, Takumu, Nakajima, Shunsuke, Okumura, Toshikatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086315/
https://www.ncbi.nlm.nih.gov/pubmed/31735795
http://dx.doi.org/10.2169/internalmedicine.3806-19
_version_ 1783509101911736320
author Honda, Shuya
Saito, Yoshinori
Sawada, Koji
Hasebe, Takumu
Nakajima, Shunsuke
Okumura, Toshikatsu
author_facet Honda, Shuya
Saito, Yoshinori
Sawada, Koji
Hasebe, Takumu
Nakajima, Shunsuke
Okumura, Toshikatsu
author_sort Honda, Shuya
collection PubMed
description A 59-year-old man who was receiving lenvatinib as a third-line tyrosine kinase inhibitor to treat hepatocellular carcinoma and multiple bone metastases complained of general fatigue four months after starting lenvatinib. A blood examination showed unexpectedly elevated serum C-reactive protein (CRP) levels. Computed tomography (CT) revealed rupture of the gallbladder wall, indicating gallbladder perforation. After conservative treatment, the patient received lenvatinib again under informed consent; however, one month later, CT revealed repeated rupture of the gallbladder wall. Gallbladder perforation had again been induced by lenvatinib. For this reason, lenvatinib is strongly considered a causative drug for gallbladder perforation.
format Online
Article
Text
id pubmed-7086315
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-70863152020-03-26 Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib Honda, Shuya Saito, Yoshinori Sawada, Koji Hasebe, Takumu Nakajima, Shunsuke Okumura, Toshikatsu Intern Med Case Report A 59-year-old man who was receiving lenvatinib as a third-line tyrosine kinase inhibitor to treat hepatocellular carcinoma and multiple bone metastases complained of general fatigue four months after starting lenvatinib. A blood examination showed unexpectedly elevated serum C-reactive protein (CRP) levels. Computed tomography (CT) revealed rupture of the gallbladder wall, indicating gallbladder perforation. After conservative treatment, the patient received lenvatinib again under informed consent; however, one month later, CT revealed repeated rupture of the gallbladder wall. Gallbladder perforation had again been induced by lenvatinib. For this reason, lenvatinib is strongly considered a causative drug for gallbladder perforation. The Japanese Society of Internal Medicine 2019-11-18 2020-03-01 /pmc/articles/PMC7086315/ /pubmed/31735795 http://dx.doi.org/10.2169/internalmedicine.3806-19 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Honda, Shuya
Saito, Yoshinori
Sawada, Koji
Hasebe, Takumu
Nakajima, Shunsuke
Okumura, Toshikatsu
Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
title Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
title_full Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
title_fullStr Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
title_full_unstemmed Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
title_short Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
title_sort repeated perforation of the gallbladder in a patient with hepatocellular carcinoma receiving lenvatinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086315/
https://www.ncbi.nlm.nih.gov/pubmed/31735795
http://dx.doi.org/10.2169/internalmedicine.3806-19
work_keys_str_mv AT hondashuya repeatedperforationofthegallbladderinapatientwithhepatocellularcarcinomareceivinglenvatinib
AT saitoyoshinori repeatedperforationofthegallbladderinapatientwithhepatocellularcarcinomareceivinglenvatinib
AT sawadakoji repeatedperforationofthegallbladderinapatientwithhepatocellularcarcinomareceivinglenvatinib
AT hasebetakumu repeatedperforationofthegallbladderinapatientwithhepatocellularcarcinomareceivinglenvatinib
AT nakajimashunsuke repeatedperforationofthegallbladderinapatientwithhepatocellularcarcinomareceivinglenvatinib
AT okumuratoshikatsu repeatedperforationofthegallbladderinapatientwithhepatocellularcarcinomareceivinglenvatinib

Ejemplares similares